Avadel Pharma (AVDL) Reports Q4 Loss of $0.46/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to Avadel Pharma (AVDL) Reports Q4 Loss of $0.46/Share

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

March 15, 2019 7:00 AM EDT

DUBLIN, Ireland, March 15, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results for the fourth quarter and full year of 2018.

We have recently announced a restructuring and other activities to focus our efforts and resources toward advancing our lead clinical-stage asset, FT218, said Greg Divis, Interim Chief Executive Officer of Avadel. Cost savings generated by the restructuring, along with hospital product cash flow, are expected to extend our cash runway into 2021.  In conjunction with the restructuring, we have engaged a third-party to... More